Read More

Lixte Biotechnology Announces Filing Of First Patent Application Resulting From Collaboration With the Netherlands Cancer Institute And The Oncode Institute To Identify The Most Promising Drug Combinations For Lead Clinical Compound, LB-100

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) reported that its the recent collaboration with the Netherlands Cancer Institute (NKI), Amsterdam, one of the world’s leading comprehensive cancer centers,

LIXT